Australia and New Zealand Endotoxin Testing Market Report and Forecast 2024-2032
Australia and New Zealand Endotoxin Testing Market Report and Forecast 2024-2032
Australia and New Zealand Endotoxin Testing Market Outlook
The Australia and New Zealand endotoxin testing market size is anticipated to grow at a CAGR of 9.5% during the forecast period of 2024-2032, driven by the increase in development of innovative, rapid, and sensitive testing methods.
Endotoxin Testing: Introduction
Endotoxin testing is a critical quality control process in pharmaceutical and medical device manufacturing, ensuring products are free from endotoxins, toxic substances released by certain bacteria. The presence of endotoxins can lead to severe reactions such as fever, septic shock, and other complications. The most common method for endotoxin testing is the Limulus Amebocyte Lysate (LAL) test, which utilizes the blood cells of horseshoe crabs to detect endotoxins with high sensitivity and specificity.
Key Trends in the Australia and New Zealand Endotoxin Testing Market
Stringent regulations by healthcare authorities worldwide to ensure drug safety and efficacy, mandating rigorous endotoxin testing. Development of innovative, rapid, and sensitive testing methods to enhance accuracy and reduce turnaround time.
Increasing adoption of automated systems for endotoxin testing, improving efficiency and reproducibility while reducing human error. Growth in the biopharmaceutical sector leads to an increased need for endotoxin testing of biologically derived products, including vaccines and cell therapies.
Heightened focus on drug safety due to global health challenges, such as the COVID-19 pandemic, amplifying the importance of rigorous contamination control.
Efforts to find sustainable alternatives to the traditional LAL test, addressing the conservation concerns related to horseshoe crab harvesting.
Australia and New Zealand Endotoxin Testing Market Segmentation
Market Breakup by Product and Services
- Endotoxin Detection Kits and Reagents
- Instruments, Systems, and Software
- Endotoxin Testing Services
- Consumables and Accessories
- Limulus Amoebocyte Lysate (LAL) Test
- Monocyte Activation Test (MAT)
- Rabbit Pyrogen Test and Recombinant C (RFC) Assay
- Pharmacies
- Online Channel
- Hypermarkets
- Gel Clot Endotoxin Test
- Chromogenic Endotoxin Test
- Turbidimetric Endotoxin Test
- Large Group
- Mid and Small Group
- Individual
- Pharmaceutical Manufacturing
- Medical Device Manufacturing
- Raw Materials Production
- Packaging Manufacture
- Pharmaceutical Companies
- Biotechnology Companies
- Medical Device Companies
- Contract Research Organization (CRO)
- Contract Manufacturing Organization (CMO)
- Academic Research Institute and Others
- Australia
- New Zealand
In Australia, the endotoxin testing market is characterized by stringent regulatory standards and a robust biotechnology sector. Strong emphasis on meeting the Therapeutic Goods Administration (TGA) guidelines for product safety, driving the demand for rigorous endotoxin testing. Adoption of advanced testing technologies and automation to increase efficiency and accuracy in endotoxin detection. Expansion of the pharmaceutical and biotechnology sectors, increasing the need for quality control measures including endotoxin testing. Increasing awareness about product safety among manufacturers and consumers, leading to a proactive approach in quality assurance practices.
In New Zealand, the market for endotoxin testing reflects the country's commitment to high-quality healthcare products. High healthcare standards driving the need for strict quality control in pharmaceuticals and medical devices, including endotoxin testing.\ Significant investment in research and development within the biotech sector, necessitating reliable endotoxin testing to ensure product safety and efficacy. Collaboration between academic institutions, research labs, and the biotech industry, fostering advancements in testing methods and technologies. A growing trend towards adopting sustainable and ethical practices in testing, including alternatives to traditional methods that reduce reliance on animal-derived substances like LAL.
Australia and New Zealand Endotoxin Testing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Viatris Inc.
- Eurofins Scientific
- Thermo Fisher Scientific
- Pall Corporation.
- Lonza Group AG
- Charles River Laboratories
- Merck KGaASteris Inc.
- Société Générale de Surveillance SA
- Sartorius AG
- GenScript
- Accugen Labs
- Sigma-Aldrich
- Nelson Laboratories and Biosynthesis
- Pacific BioLabs
*Please Note:* The report will take 7 business days to complete, after order confirmation.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Australia and New Zealand Endotoxin Testing Market Overview
- 3.1 Australia and New Zealand Endotoxin Testing Market Historical Value (2017-2023)
- 3.2 Australia and New Zealand Endotoxin Testing Market Forecast Value (2024-2032)
- 4 Australia and New Zealand Endotoxin Testing Market Dynamics
- 4.1 Market Drivers and Constraints
- 4.2 SWOT Analysis
- 4.3 Porter’s Five Forces Model
- 4.4 Key Demand Indicators
- 4.5 Key Price Indicators
- 4.6 Industry Events, Initiatives, and Trends
- 4.7 Value Chain Analysis
- 5 Australia and New Zealand Endotoxin Testing Market Segmentation
- 5.1 Australia and New Zealand Endotoxin Testing Market by Product & Services
- 5.1.1 Market Overview
- 5.1.2 Endotoxin Detection Kits & Reagents
- 5.1.3 Instruments, Systems, and Software
- 5.1.4 Endotoxin Testing Services
- 5.1.5 Consumables & Accessories
- 5.2 Australia and New Zealand Endotoxin Testing Market by Test Type
- 5.2.1 Market Overview
- 5.2.2 Limulus Amoebocyte Lysate (LAL) Test
- 5.2.3 Monocyte Activation Test (MAT)
- 5.2.4 Rabbit Pyrogen Test and Recombinant C (RFC) Assay
- 5.3 Australia and New Zealand Endotoxin Testing Market by Distribution Channel
- 5.3.1 Market Overview
- 5.3.2 Pharmacies
- 5.3.3 Online Channel
- 5.3.4 Hypermarkets
- 5.4 Australia and New Zealand Endotoxin Testing Market by Method
- 5.4.1 Market Overview
- 5.4.2 Gel Clot Endotoxin Test
- 5.4.3 Chromogenic Endotoxin Test
- 5.4.4 Turbidimetric Endotoxin Test
- 5.5 Australia and New Zealand Endotoxin Testing Market by Mode of Purchase
- 5.5.1 Market Overview
- 5.5.2 Large Group
- 5.5.3 Mid and Small Group
- 5.5.4 Individual
- 5.6 Australia and New Zealand Endotoxin Testing Market by Applications
- 5.6.1 Market Overview
- 5.6.2 Pharmaceutical Manufacturing
- 5.6.3 Medical Device Manufacturing
- 5.6.4 Raw Materials Production
- 5.6.5 Packaging Manufacture
- 5.7 Australia and New Zealand Endotoxin Testing Market by End User
- 5.7.1 Market Overview
- 5.7.2 Pharmaceutical Companies
- 5.7.3 Biotechnology Companies
- 5.7.4 Medical Device Companies
- 5.7.5 Contract Research Organization (CRO)
- 5.7.6 Contract Manufacturing Organization (CMO)
- 5.7.7 Academic Research Institute and Others
- 5.8 Australia and New Zealand Endotoxin Testing Market by Country
- 5.8.1 Market Overview
- 5.8.2 Australia
- 5.8.3 New Zealand
- 6 Patent Analysis
- 6.1 Analysis by Type of Patent
- 6.2 Analysis by Publication year
- 6.3 Analysis by Issuing Authority
- 6.4 Analysis by Patent Age
- 6.5 Analysis by CPC Analysis
- 6.6 Analysis by Patent Valuation
- 6.7 Analysis by Key Players
- 7 Grants Analysis
- 7.1 Analysis by year
- 7.2 Analysis by Amount Awarded
- 7.3 Analysis by Issuing Authority
- 7.4 Analysis by Grant Application
- 7.5 Analysis by Funding Institute
- 7.6 Analysis by NIH Departments
- 7.7 Analysis by Recipient Organization
- 8 Funding Analysis
- 8.1 Analysis by Funding Instances
- 8.2 Analysis by Type of Funding
- 8.3 Analysis by Funding Amount
- 8.4 Analysis by Leading Players
- 8.5 Analysis by Leading Investors
- 8.6 Analysis by Geography
- 9 Partnership and Collaborations Analysis
- 9.1 Analysis by Partnership Instances
- 9.2 Analysis by Type of Partnership
- 9.3 Analysis by Leading Players
- 9.4 Analysis by Geography
- 10 Regulatory Framework
- 10.1 Regulatory Overview
- 11 Supplier Landscape
- 11.1 Viatris Inc.
- 11.1.1 Financial Analysis
- 11.1.2 Product Portfolio
- 11.1.3 Demographic Reach and Achievements
- 11.1.4 Mergers and Acquisitions
- 11.1.5 Certifications
- 11.2 Eurofins Scientific
- 11.2.1 Financial Analysis
- 11.2.2 Product Portfolio
- 11.2.3 Demographic Reach and Achievements
- 11.2.4 Mergers and Acquisitions
- 11.2.5 Certifications
- 11.3 Thermo Fisher Scientific
- 11.3.1 Financial Analysis
- 11.3.2 Product Portfolio
- 11.3.3 Demographic Reach and Achievements
- 11.3.4 Mergers and Acquisitions
- 11.3.5 Certifications
- 11.4 Pall Corporation.
- 11.4.1 Financial Analysis
- 11.4.2 Financial Portfolio
- 11.4.3 Demographic Reach and Achievements
- 11.4.4 Mergers and Acquisitions
- 11.4.5 Certifications
- 11.5 Lonza Group AG
- 11.5.1 Financial Analysis
- 11.5.2 Product Portfolio
- 11.5.3 Demographic Reach and Achievements
- 11.5.4 Mergers and Acquisitions
- 11.5.5 Certifications
- 11.6 Charles River Laboratories
- 11.6.1 Financial Analysis
- 11.6.2 Product Portfolio
- 11.6.3 Demographic Reach and Achievements
- 11.6.4 Mergers and Acquisitions
- 11.6.5 Certifications
- 11.7 Merck KGaA
- 11.7.1 Financial Analysis
- 11.7.2 Product Portfolio
- 11.7.3 Demographic Reach and Achievements
- 11.7.4 Mergers and Acquisitions
- 11.7.5 Certifications
- 11.8 Steris Inc.
- 11.8.1 Financial Analysis
- 11.8.2 Product Portfolio
- 11.8.3 Demographic Reach and Achievements
- 11.8.4 Mergers and Acquisitions
- 11.8.5 Certifications
- 11.9 Société Générale de Surveillance SA
- 11.9.1 Financial Analysis
- 11.9.2 Product Portfolio
- 11.9.3 Demographic Reach and Achievements
- 11.9.4 Mergers and Acquisitions
- 11.9.5 Certifications
- 11.10 Sartorius AG
- 11.10.1 Financial Analysis
- 11.10.2 Product Portfolio
- 11.10.3 Demographic Reach and Achievements
- 11.10.4 Mergers and Acquisitions
- 11.10.5 Certifications
- 11.11 GenScript
- 11.11.1 Financial Analysis
- 11.11.2 Product Portfolio
- 11.11.3 Demographic Reach and Achievements
- 11.11.4 Mergers and Acquisitions
- 11.11.5 Certifications
- 11.12 Accugen Labs
- 11.12.1 Financial Analysis
- 11.12.2 Product Portfolio
- 11.12.3 Demographic Reach and Achievements
- 11.12.4 Mergers and Acquisitions
- 11.12.5 Certifications
- 11.13 Sigma-Aldrich
- 11.13.1 Financial Analysis
- 11.13.2 Product Portfolio
- 11.13.3 Demographic Reach and Achievements
- 11.13.4 Mergers and Acquisitions
- 11.13.5 Certifications
- 11.14 Nelson Laboratories and Biosynthesis
- 11.14.1 Financial Analysis
- 11.14.2 Product Portfolio
- 11.14.3 Demographic Reach and Achievements
- 11.14.4 Mergers and Acquisitions
- 11.14.5 Certifications
- 11.15 Pacific BioLabs
- 11.15.1 Financial Analysis
- 11.15.2 Product Portfolio
- 11.15.3 Demographic Reach and Achievements
- 11.15.4 Mergers and Acquisitions
- 11.15.5 Certifications
- 12 Australia and New Zealand Endotoxin Testing Market - Distribution Model (Additional Insight)
- 12.1 Overview
- 12.2 Potential Distributors
- 12.3 Key Parameters for Distribution Partner Assessment
- 13 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 14 Company Competitiveness Analysis (Additional Insight)
- 14.1 Very Small Companies
- 14.2 Small Companies
- 14.3 Mid-Sized Companies
- 14.4 Large Companies
- 14.5 Very Large Companies
- 15 Payment Methods (Additional Insight)
- 15.1 Government Funded
- 15.2 Private Insurance
- 15.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook